Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 60.85% | -5.94% | 132.98% | -10.61% | -3.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.85% | -5.94% | 132.98% | -10.61% | -3.21% |
| Cost of Revenue | -2.71% | -11.31% | -24.08% | -20.19% | 15.13% |
| Gross Profit | 227.68% | 0.67% | 389.75% | -0.80% | -31.74% |
| SG&A Expenses | -3.88% | 21.09% | 16.96% | 2.39% | -0.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.32% | 5.18% | -3.57% | -7.57% | 6.70% |
| Operating Income | 131.76% | -95.47% | 572.05% | -13.05% | -34.21% |
| Income Before Tax | 120.84% | -62.58% | 480.48% | -11.03% | -38.69% |
| Income Tax Expenses | 45.45% | 9.44% | 1.69% | 308.77% | 100.59% |
| Earnings from Continuing Operations | 120.23% | -62.16% | 475.52% | -11.93% | -38.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 120.23% | -62.16% | 475.52% | -11.93% | -38.84% |
| EBIT | 131.76% | -95.47% | 572.05% | -13.05% | -34.21% |
| EBITDA | 132.28% | -97.59% | 577.38% | -13.26% | -34.45% |
| EPS Basic | 119.87% | -59.44% | 469.01% | -10.07% | -36.08% |
| Normalized Basic EPS | 120.47% | -59.83% | 473.92% | -15.15% | -35.93% |
| EPS Diluted | 119.74% | -67.39% | 461.16% | -10.07% | -36.99% |
| Normalized Diluted EPS | 119.90% | -59.83% | 463.43% | -15.15% | -35.93% |
| Average Basic Shares Outstanding | 1.78% | 1.72% | 1.76% | 1.71% | 2.03% |
| Average Diluted Shares Outstanding | 4.76% | 1.72% | 4.70% | 1.71% | 2.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |